Boston Scientific Corp (BSX)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	1,591,000	698,000	1,041,000	-82,000	4,700,000
Total stockholders’ equity	US$ in thousands	19,282,000	17,573,000	16,623,000	15,327,000	13,877,000
ROE		8.25%	3.97%	6.26%	-0.54%	33.87%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $1,591,000K ÷ $19,282,000K
= 8.25%

Based on the data provided, the return on equity (ROE) of Boston Scientific Corp. has varied over the years. In 2019, the company achieved a high ROE of 33.85%, indicating strong profitability and efficiency in generating returns for shareholders. However, in 2020, the ROE turned negative at -0.74%, suggesting a period of unprofitability or inefficiency in the use of equity.

Subsequently, in 2021, the ROE improved to 5.92%, but remained relatively low compared to previous years. This was followed by a further increase in 2022 to 3.64%, indicating a slight improvement in profitability and efficiency.

Most recently, in 2023, Boston Scientific Corp. saw a notable rise in ROE to 8.14%, suggesting an increase in profitability and efficiency in leveraging shareholder equity compared to the previous year.

Overall, the trend in ROE for Boston Scientific Corp. reflects variability in the company's ability to generate returns on the shareholder equity invested. It is essential for the company to focus on sustaining and enhancing its profitability and operational efficiency to ensure consistent and favorable ROE figures in the future.